After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction

Area of Science:

• Cardiology
• Internal Medicine
• Clinical Therapeutics

Background:

• Heart failure with preserved ejection fraction (HF-PEF) constitutes a significant portion of heart failure cases.
• Limited evidence-based medical therapies exist for HF-PEF management.
• The TOPCAT trial yielded neutral results for spironolactone in HF-PEF, creating a clinical challenge.

Purpose of the Study:

• To outline a clinical management approach for patients with HF-PEF.
• To synthesize available clinical trial data and expert consensus for HF-PEF treatment.
• To address the ongoing clinical dilemma in managing HF-PEF.

Main Methods:

• Review of available clinical trials.
• Synthesis of expert consensus guidelines.
• Development of a structured clinical management approach.

Main Results:

• The review synthesizes existing data on HF-PEF management.
• It highlights the lack of definitive therapeutic options.
• It provides a framework for clinical decision-making.

Conclusions:

• Effective medical therapies for HF-PEF remain limited.
• A comprehensive approach integrating trial data and expert opinion is necessary for managing HF-PEF.
• Further research is needed to establish evidence-based treatments for HF-PEF.